Table 2.
Pathological Background
| Characteristics | Number of patients (%) |
|---|---|
| Primary tumor* | |
| T1 | 11 (31) |
| T2 | 19 (54) |
| T3 | 5 (14) |
| Regional lymph nodes* | |
| N0 | 18 (51) |
| N1 | 9 (26) |
| N2 | 6 (17) |
| N3 | 2 (6) |
| Distant metastasis* | |
| M0 | 35 (100) |
| M1 | 0 (0) |
| Stage* | |
| I | 6 (17) |
| II | 19 (54) |
| III | 10 (29) |
| Lymphatic invasion* | |
| Absent | 27 (77) |
| Present | 8 (23) |
| Vascular invasion* | |
| Absent | 31 (89) |
| Present | 4 (11) |
| Ki-67 index | |
| <14 | 12 (34) |
| ≧14 | 23 (66) |
| NSAS nuclear grade | |
| 1 | 25 (71) |
| 2 | 5 (14) |
| 3 | 5 (14) |
| Estrogen receptor expression | |
| Negative | 7 (20) |
| Positive | 28 (80) |
| Progesterone receptor expression | |
| Negative | 6 (17) |
| Positive | 29 (83) |
| HER2 overexpression/amplification | |
| Negative | 30 (86) |
| Positive | 5 (14) |
*
According to the AJCC cancer staging system [22].